Treatments and diagnostics for cancers
AssigneeWayne State University
InventorsQingping Dou, Huanjie Yang, Elisabeth I. Heath
Life of this patent
Estimating the term…
Abstract
Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
Claims34
A method of providing an anti-cancer effect in a subject having a solid tumor cancer or a liquid cancer comprising administering therapeutically effective amounts of Galeterone and a proteasome inhibitor to the subject, thereby providing an anti-cancer effect in the subject.
A method of potentiating the anti-cancer effect of Galeterone comprising administering a therapeutically effective amount of a proteasome inhibitor in combination with a therapeutically effective amount of Galeterone to a subject in need thereof.
A composition comprising Galeterone and a proteasome inhibitor.
A method of monitoring an anti-cancer effect of a castration-resistant prostate cancer (CRPC) therapeutic composition following its administration to a subject comprising detecting an androgen receptor (AR) cleavage product, a Poly (ADP-ribose) polymerase (PARP) cleavage product, and/or a Spectrin α2 cleavage product in a sample obtained from the subject following the administration wherein presence of the AR cleavage product, PARP cleavage product, and/or a Spectrin α2 cleavage product is indicative of the anti-cancer effect.
A method of monitoring an anti-cancer effect of a castration-resistant prostate cancer (CRPC) therapeutic composition following its administration to a subject comprising detecting a Poly (ADP-ribose) polymerase (PARP) cleavage product or a Spectrin α2 cleavage product in a sample obtained from the subject following the administration wherein presence of the PARP cleavage product or the Spectrin α2 cleavage product is indicative of the anti-cancer effect.
A method to target 19S proteasome-associated DUBs and 20s proteasome comprising administering therapeutically effective amounts of Galeterone and a proteasome inhibitor in vivo or in vitro thereby targeting 19S proteasome-associated DUBs with Galeterone and 20s proteasome with the proteasome inhibitor.
A method to target DUBs in solid and/or liquid tumors comprising administering a therapeutically effective amount of Galeterone to a subject in need thereof thereby targeting DUBs in solid and/or liquid tumors.
Dependencies are inferred from the claim text.